肠易激综合征诊断及药物治疗的研究进展

Progress in the diagnosis and pharmacotherapy of irritable bowel syndrome

肠易激综合征(irritable bowel syndrome,IBS)是一种常见的功能性肠道疾病,发病率较高,严重影响患者的生活质量。本病病因和发病机制复杂,肠道感染、菌群紊乱、黏膜免疫炎症反应、脑-肠轴功能紊乱、胃肠道动力异常、内脏高敏性和精神心理异常等多种因素参与发病。目前,IBS诊断主要基于症状标准,随着基础研究和临床研究的日渐深入,其潜在生物标记物受到关注。本文就IBS诊断方法及其治疗药物的研究现状、临床疗效及安全性作一综述。

Irritable bowel syndrome(IBS)is one of the most common functional gastrointestinal disorders with high incidence and serious impact on the quality of patients’lives.The etiology and pathogenesis of IBS are complex,gastrointestinal infection,intestinal flora disorder,mucosal immune-inflammatory responses,dysfunction of the brain-gut axis,abnormal intestinal motility,visceral hypersensitivity,and mental disorder are associated with IBS.Currently,the diagnosis of IBS is mainly based on symptom.With the advances in basic and clinical research,potential biomarkers have attracted attention.This paper summarizes the diagnostic methods,as well as the research status,clinical efficacy,and safety concern of medication.